{"@type": "dcat:Dataset", "accessLevel": "public", "bureauCode": ["009:25"], "contactPoint": {"@type": "vcard:Contact", "fn": "NIH", "hasEmail": "mailto:info@nih.gov"}, "description": "Background\n          Nitric oxide (NO) production is increased among patients with human immunodeficiency virus (HIV) infection and also among those with tuberculosis (TB). In this study we sought to determine if there was increased NO production among patients with HIV/TB coinfection and the effect of four weeks chemotherapy on this level.\n        \n        \n          Methods\n          19 patients with HIV/TB coinfection were studied. They were treated with standard four drug antitubercular therapy and sampled at baseline and four weeks. 20 patients with HIV infection, but no opportunistic infections, were disease controls and 20 individuals were healthy controls. Nitrite and citrulline, surrogate markers for NO, were measured spectrophotometrically.\n        \n        \n          Results\n          The mean age of HIV/TB patients was 28.4 \u00b1 6.8 years and CD4 count was 116 \u00b1 36.6/mm. Mean nitrite level among HIV/TB coinfected was 207.6 \u00b1 48.8 nmol/ml. This was significantly higher than 99.7 \u00b1 26.5 nmol/ml, the value for HIV infected without opportunistic infections and 46.4 \u00b1 16.2 nmol/ml, the value for healthy controls (p value < 0.01). The level of HIV/TB coinfected NO in patients declined to 144.5 \u00b1 34.4 nmol/ml at four weeks of therapy (p value < 0.05). Mean citrulline among HIV/TB coinfected was 1446.8 \u00b1 468.8 nmol/ml. This was significantly higher than 880.8 \u00b1 434.8 nmol/ml, the value for HIV infected without opportunistic infections and 486.6 \u00b1 212.5 nmol/ml, the value for healthy controls (p value < 0.01). Levels of citrolline in HIV/TB infected declined to 1116.2 \u00b1 388.6 nmol/ml at four weeks of therapy (p value < 0.05).\n        \n        \n          Conclusions\n          NO production is elevated among patients with HIV infection, especially so among HIV/TB coinfected patients, but declines significantly following 4 weeks of antitubercular therapy.", "distribution": [{"@type": "dcat:Distribution", "description": "Visit the original government dataset for complete information, documentation, and data access.", "downloadURL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC119853/", "mediaType": "text/html", "title": "Official Government Data Source"}], "identifier": "https://healthdata.gov/api/views/nxn7-3vfx", "issued": "2025-07-14", "keyword": ["antitubercular-therapy", "hiv-tb-coinfection", "nih", "nitric-oxide", "nitrite-levels"], "landingPage": "https://healthdata.gov/d/nxn7-3vfx", "modified": "2025-09-06", "programCode": ["009:035"], "publisher": {"@type": "org:Organization", "name": "National Institutes of Health"}, "theme": ["NIH"], "title": "Antitubercular therapy decreases nitric oxide production in HIV/TB coinfected patients"}